Molecular Features of Gastrointestinal Stromal Tumors: A Single Referral Cancer Center Experience
Anticancer Research · 2026
DOI: 10.21873/anticanres.18180 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Angela Zupa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Anatomical Pathology Department, IRCCS CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Proto-Oncogene Proteins c-kit, Receptor, Platelet-Derived Growth Factor alpha, Gastrointestinal Neoplasms.
Abstract (Originalsprache)
BACKGROUND/AIM: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the digestive tract. They frequently harbor mutations in KIT proto-oncogene, receptor tyrosine kinase (KIT) (70-80%) and platelet-derived growth factor receptor alpha (PDGFRA) (10-15%) genes, responding effectively to tyrosine kinase inhibitors (TKIs). Accurate genotyping is crucial for diagnosis and therapeutic management. This study reports a decade-long experience, detailing the epidemiological, pathological, and molecular characteristics of GISTs in a single-center cohort. PATIENTS AND METHODS: Twenty-nine patients diagnosed with GIST (stomach, small bowel, colon, and peritoneum) at IRCCS CROB, Italy, between 2012 and 2021 were enrolled. Molecular analysis was performed using Sanger sequencing and Next-Generation Sequencing (NGS). RESULTS: Twenty-three patients (85%) harbored KIT mutations, while four (15%) had PDGFRA mutations. Among KIT-mutated cases, five (22%) presented the p.Ala502_Tyr503dup duplication in exon 9. Elevated Ki-67 and a mitotic index of 3-7/50 high-power field (HPF) were associated with high recurrence risk. Eighteen patients (78%) exhibited mutations in exon 11: 8 (44%) were point mutations, 5 (28%) deletions, and 5 (28%) complex deletions. Point mutations at codons 557, 560, and 603 correlated with high recurrence risk, whereas mutations at codons 559 and 599 linked to low-risk disease. Most deletions and complex deletions showed high recurrence risk and Ki-67 >10%. PDGFRA mutations were located in exon 18 (2 complex deletions, 2 point mutations including p.D842V); three of these cases showed low-to-moderate recurrence risk (Ki-67 ≤8%). CONCLUSION: This study characterizes the clinicopathological and molecular profiles of 29 Caucasian GIST patients, reinforcing the critical role of molecular stratification in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Anatomical Pathology Department, IRCCS CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.
- Department of Onco-Hematology, Division of Medical Oncology, IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.
- Experimental Oncology Unit, IRCCS CROB Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy.
- Laboratory of Preclinical and Translational Research, IRCCS-CROB Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy.
- Anatomical Pathology Department, IRCCS CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; giuseppina.improta@gmail.com giuseppina.improta@crob.it.
Zitieren
APA
Zupa, A., Vita, G., Tartarone, A., Omer, L. C., Calice, G., & Improta, G. (2026). Molecular Features of Gastrointestinal Stromal Tumors: A Single Referral Cancer Center Experience. Anticancer Research. https://doi.org/10.21873/anticanres.18180
Vancouver
Zupa A, Vita G, Tartarone A, Omer LC, Calice G, Improta G. Molecular Features of Gastrointestinal Stromal Tumors: A Single Referral Cancer Center Experience. Anticancer Research. 2026. doi:10.21873/anticanres.18180
BibTeX
@article{Zupa2026,
author = {Zupa, Angela and Vita, Giulia and Tartarone, Alfredo and Omer, Ludmila Carmen and Calice, Giovanni and Improta, Giuseppina},
title = {Molecular Features of Gastrointestinal Stromal Tumors: A Single Referral Cancer Center Experience},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.18180}
}
EUVIMED